GleamWall
中文EN

IFRX InflaRx N.V. IFRS

Pharmaceutical Preparations · Nasdaq · SEC CIK 1708688 · Reporting currency EUR · Fiscal year ends 12/31

Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY-82.3%
TTM net income YoY0.9%
TTM EPS YoY12.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin-24,677.9%
Operating margin—
Net margin-155,582.1%
FCF margin—
EBITDA margin—

Returns

ROE-624.6%
ROA-69.5%
ROIC (approx.)—
Asset turnover0.00x

Leverage & solvency

Liabilities / assets24.7%
Debt / equity0.00x
Current ratio4.13x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.77x
Accruals ratio-15.7%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Unit: EUR 2025Q2*2025-06-302024Q2*2024-06-302023Q2*2023-06-302022Q2*2022-06-302021Q2*2021-06-302019Q2*2019-06-302018Q2*2018-06-30
Income statement
Revenue39,4326,357—————
Cost of revenue2.40M348,153—————
Gross profit-2.36M-341,796———-16.14M-8.19M
R&D expense7.20M10.02M10.92M11.18M11.30M12.50M5.03M
SG&A expense3.28M3.23M3.54M4.35M2.70M3.65M3.16M
Interest expense3,3558,7325,0522,243305388,00037,000
Income tax———00——
Net income-14.42M-13.85M-8.20M465,376-14.78M-15.27M-2.44M
EPS (basic)-0.21-0.24-0.140.01—-0.59-0.10
EPS (diluted)-0.21-0.24-0.140.01-0.33-0.59-0.10
Weighted avg. shares (diluted)—————25,96424,890
Banking
Net interest income-323-2,056-363————
Balance sheet
Cash & equivalents13.00M19.15M19.52M15.42M72.36M54.06M156.07M
Receivables—23,727—————
Inventory5.04M9.64M578,705————
Current assets66.17M91.30M112.22M112.13M—142.53M—
PP&E, netmay include right-of-use assets (IFRS)247,027272,446296,382231,133—1.64M—
Intangibles—————453,000—
Total assets73.44M93.04M132.96M114.63M—144.92M—
Current liabilities16.16M10.24M7.47M11.29M—13.35M—
Long-term debt———2.15M———
Total debt———2.15M———
Total liabilities16.40M10.88M8.32M12.50M—14.05M—
Shareholders' equity57.04M82.16M124.65M102.13M123.61M130.87M161.78M
Net debt———-13.27M———
Cash flow statement
Operating cash flow———————

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· Amounts are in the company's reporting currency, EUR, not USD; the site does no currency conversion.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.